About Vaxart
Vaxart is a company based in San Francisco (United States) founded in 2004.. Vaxart has raised $57.97 million across 11 funding rounds from investors including HHS, Care Capital Management and Care Capital. The company has 115 employees as of December 31, 2024. Vaxart offers products and services including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform. Vaxart operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Biological E, among others.
- Headquarter San Francisco, United States
- Employees 115 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vaxart, Inc.
-
Annual Revenue
$28.7 M288.94as on Dec 31, 2024
-
Net Profit
$-66.95 M18.82as on Dec 31, 2024
-
EBITDA
$-61.89 M21.5as on Dec 31, 2024
-
Total Equity Funding
$57.97 M (USD)
in 11 rounds
-
Latest Funding Round
$18.4 M (USD), Series C
Jan 08, 2015
-
Investors
HHS
& 5 more
-
Employee Count
115
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vaxart
Vaxart is a publicly listed company on the OTC with ticker symbol VXRT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vaxart
Vaxart offers a comprehensive portfolio of products and services, including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Vaccines delivered as oral pills for immunity against viral diseases.
Platform for developing oral recombinant vaccines.
Platform focused on enhancing mucosal immune responses.
Unlock access to complete
Unlock access to complete
Funding Insights of Vaxart
Vaxart has successfully raised a total of $57.97M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $18.4 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series C — $18.4M
-
First Round
First Round
(01 Apr 2007)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2015 | Amount | Series C - Vaxart | Valuation | Care Capital Management |
|
| Aug, 2013 | Amount | Series C - Vaxart | Valuation |
investors |
|
| Jun, 2012 | Amount | Series B - Vaxart | Valuation | Care Capital , Quantum Technology Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vaxart
Vaxart has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Care Capital Management and Care Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Life sciences startups are funded by a non-profit angel network.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vaxart
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vaxart
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vaxart Comparisons
Competitors of Vaxart
Vaxart operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Generate Biomedicines, HOOKIPA Pharma and Biological E, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vaxart
Frequently Asked Questions about Vaxart
When was Vaxart founded?
Vaxart was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Where is Vaxart located?
Vaxart is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Vaxart a funded company?
Vaxart is a funded company, having raised a total of $57.97M across 11 funding rounds to date. The company's 1st funding round was a Series B of $16.87M, raised on Apr 01, 2007.
How many employees does Vaxart have?
As of Dec 31, 2024, the latest employee count at Vaxart is 115.
What is the annual revenue of Vaxart?
Annual revenue of Vaxart is $28.7M as on Dec 31, 2024.
What does Vaxart do?
Founded in 2004 and based in San Francisco, United States, oral vaccines targeting infectious diseases are developed by Vaxart within the biotechnology sector. A proprietary delivery platform is employed to produce recombinant vaccines, with the pipeline covering seasonal influenza, norovirus, RSV, HSV-2, avian influenza, and Ebola. Vaccines addressing influenza treatment are also included in the offerings.
Who are the top competitors of Vaxart?
Vaxart's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
What products or services does Vaxart offer?
Vaxart offers Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform.
Is Vaxart publicly traded?
Yes, Vaxart is publicly traded on OTC under the ticker symbol VXRT.
Who are Vaxart's investors?
Vaxart has 6 investors. Key investors include HHS, Care Capital Management, Care Capital, Quantum Technology Partners, and Life Science Angels.
What is Vaxart's ticker symbol?
The ticker symbol of Vaxart is VXRT on OTC.